Ocular Surface Disease
Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.
What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career clinicians ready to think beyond the bedside and explore the business of medicine.
Taking place from 7–9 June 2025 in Lisbon, Portugal, the SOE Congress is one of Europe's leading multi-specialty ophthalmology meetings. With a world-class scientific programme, this in-person event offers a rich mix of symposia, live surgery, debates, workshops, mystery cases and updates ...
In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.
Dry eye disease (DED) is a prevalent ocular condition characterized by discomfort, visual disturbances and tear film instability due to insufficient tear production or rapid tear evaporation.1Â With an increasing global incidence (i.e. up to 50%) and its significant impact ...
Dry eye disease (DED) is a multifactorial condition of the ocular surface and tears. It is frequently encountered in ocular practices, comprising nearly 33% of visits in the USA, and with an estimated global prevalence ranging between 5% and 50%.1,2Â The chronic symptoms ...
Reproxalap is a reactive aldehyde species (RASP) inhibitor believed to mitigate inflammatory conditions such as dry eye disease (DED), allergic conjunctivitis and uveitis.1 RASP are pro-inflammatory molecules that covalently bind to thiol and amino groups expressed on various receptors and ...
The Boston Keratoprosthesis type II (BK2) device may be the only viable option to salvage vision in patients with severe cicatrizing ocular surface disease. The prior BK2 model was modified to the present day (click-on) model in 2009. The clinical outcomes ...
Demodex blepharitis is a highly prevalent lid margin disease that is commonly missed or misdiagnosed by eye care professionals. The disease is caused by an infestation of Demodex mites – tiny parasites that live in the eyelash follicles and feed on ...
The prevalence of both dry eye disease and sleep apnoea has steadily increased in the USA.1Â Importantly, new research reveals the need for multispecialty collaboration based on evidence that patients may be at risk for eye irritation secondary to airflow ...
Dry eye disease (DED) is an inflammatory condition of the cornea and conjunctiva that is characterized by tear-film instability and increased tear osmolarity.1–3 While DED is traditionally viewed as a chronic condition, many patients experience episodic exacerbations of the disease, ...
It was a pleasure to interview Marie Bannier-Hélaouët (Hubrecht Institute, Royal Netherlands Academy of Arts and Sciences, Utrecht, Netherlands) about her fascinating research into lachrymal gland organoids, which have great potential for the future treatment of lachrymal gland ...
Over the past few years, we have witnessed an increasing awareness of the importance of treating ocular surface disease (OSD). Diagnoses such as dry eye and blepharitis, which were historically under-appreciated, now command attention from the ophthalmologist and investment from ...
Dry eye disease is a chronic condition that affects the corneal surface, and is clinically characterized by loss of tear volume and increased evaporation of tears.1,2Â The definition of dry eye disease has evolved since it was first recognized over 30 ...
Jennifer Loh (South Florida Vision Associates, Fort Lauderdale, Florida, USA) discusses unmet needs in the treatment of dry eye, and gives an overview of the TearCare system and the efficacy and safety findings of the OLYMPIA clinical trial. Questions: 1. What ...
Cynthia Matossian discusses the latest technological and pharmaceutical advancements that are easing the burden of administering eye drops, both for patients and their caregivers.
Log into your Touch Account
Earn and track your CME credits on the go, save articles for later, and follow the latest congress coverage.
Sign up with an Email
Or use a .
This Functionality is for
Members Only
Explore the latest in medical education and stay current in your field. Create a free account to track your learning.
